Edwige Nicodème
Galderma (Switzerland) · 39 works · 3,876 citations · h-index 21
Top works
- Suppression of inflammation by a synthetic histone mimic
- Discovery and Characterization of Small Molecule Inhibitors of the BET Family Bromodomains
- Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans
- Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains
- Identification of a novel series of BET family bromodomain inhibitors: Binding mode and profile of I-BET151 (GSK1210151A)
- Refractory period phenomenon in the induction of tissue factor expression on endothelial cells
- From ApoA1 upregulation to BET family bromodomain inhibition: Discovery of I-BET151
- The Discovery of I-BET726 (GSK1324726A), a Potent Tetrahydroquinoline ApoA1 Up-Regulator and Selective BET Bromodomain Inhibitor
- Microsomal Triacylglycerol Transfer Protein Prevents Presecretory Degradation of Apolipoprotein B‐100
- Substituted 2-[(4-Aminomethyl)phenoxy]-2-methylpropionic Acid PPARα Agonists. 1. Discovery of a Novel Series of Potent HDLc Raising Agents
- Identification of Liver Receptor Homolog-1 as a Novel Regulator of Apolipoprotein AI Gene Transcription
- Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia
- Development of a Topical Treatment for Psoriasis Targeting RORγ: From Bench to Skin
- Identification of Domains in Apolipoprotein B100 That Confer a High Requirement for the Microsomal Triglyceride Transfer Protein
- Urokinase and Type I Plasminogen Activator Inhibitor Production by Normal Human Hepatocytes: Modulation by Inflammatory Agents
- Quantitative trait locus mapping of genes that regulate HDL cholesterol in SM/J and NZB/B1NJ inbred mice
- Discovery and Optimization of Potent, Selective, and in Vivo Efficacious 2-Aryl Benzimidazole BCATm Inhibitors
- The Discovery of in Vivo Active Mitochondrial Branched-Chain Aminotransferase (BCATm) Inhibitors by Hybridizing Fragment and HTS Hits
- Naphthyridines as Novel BET Family Bromodomain Inhibitors
- A Potent and Selective Kallikrein-5 Inhibitor Delivers High Pharmacological Activity in Skin from Patients with Netherton Syndrome